Specific keynote: genome copy number abnormalities in ovarian cancer

Untargeted metabolomics of cervicovaginal fluid in patients with ovarian cancer.

Journal of clinical and translational science·2026

Psychosocial Stress Exposures and Advanced Disease at Ovarian Cancer Diagnosis.

Cancer control : journal of the Moffitt Cancer Center·2026

Characterizing the composition and diversity of the vaginal microbiome in ovarian cancer.

Communications medicine·2026

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Gynecologic oncology·2026

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer.

Nature communications·2026

Molecular characterization of NSMP endometrial cancer and its relevance for treatment.

Gynecologic oncology·2026

High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.

Gynecologic oncology·2026

Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model.

Gynecologic oncology·2026

The science and conduct of surgical trials in gynecologic oncology: A practical framework.

Gynecologic oncology·2026

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Gynecologic oncology·2026

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

Gynecologic oncology·2026

The dichotomy of central nervous system cancer burden: A global analysis revealing diagnosis-driven epidemics and therapy-resistant mortality.

Neuro-oncology advances·2026

A Heterogeneous Phenotypic Presentation of a PALB2 Mutation Carrier With Multiple Metachronous Primary Malignancies: A Case Report.

Cureus·2026

Systematic evaluation of genetic polymorphisms in carcinogen metabolizing enzymes associated with oral potentially malignant disorders progression to oral cancer risk.

Journal of dental sciences·2026

Expert Consensus on the Management of Obesity in Older Adults (2026 Edition).

Aging medicine (Milton (N.S.W))·2026

Aligning awareness, systems and policy to increase equitable access to genomically driven cancer care.

BMJ oncology·2026

The impact of gut microbiota on insulin resistance in polycystic ovary syndrome: mechanisms and therapeutic prospects.

Frontiers in cellular and infection microbiology·2026

Related Experiment Videos

Specific keynote: genome copy number abnormalities in ovarian cancer

Related Concept Videos

Untargeted metabolomics of cervicovaginal fluid in patients with ovarian cancer.

Psychosocial Stress Exposures and Advanced Disease at Ovarian Cancer Diagnosis.

Characterizing the composition and diversity of the vaginal microbiome in ovarian cancer.

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.

Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer.

Molecular characterization of NSMP endometrial cancer and its relevance for treatment.

High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.

Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model.

The science and conduct of surgical trials in gynecologic oncology: A practical framework.

Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.

The dichotomy of central nervous system cancer burden: A global analysis revealing diagnosis-driven epidemics and therapy-resistant mortality.

A Heterogeneous Phenotypic Presentation of a PALB2 Mutation Carrier With Multiple Metachronous Primary Malignancies: A Case Report.

Systematic evaluation of genetic polymorphisms in carcinogen metabolizing enzymes associated with oral potentially malignant disorders progression to oral cancer risk.

Expert Consensus on the Management of Obesity in Older Adults (2026 Edition).

Aligning awareness, systems and policy to increase equitable access to genomically driven cancer care.

The impact of gut microbiota on insulin resistance in polycystic ovary syndrome: mechanisms and therapeutic prospects.

Related Experiment Videos

Specific keynote: genome copy number abnormalities in ovarian cancer

Related Concept Videos

Related Articles